DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1759)

Non-Small-Cell Lung Cancer | Access & Reimbursement | Detailed, Expanded Analysis (US)

Non-Small-Cell Lung Cancer | Access & Reimbursement | Detailed, Expanded Analysis (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

NSCLC is one of the most dynamic oncology indications with multiple premium-priced, targeted therapies available. Increasing segmentation in this market by biomarker-driven approvals has led to improved efficacy outcomes for patients. However, increased costs due to the expanded use of branded agents is driving up the overall cost of treatment in many market segments. In an increasingly competitive and highly fragmented market, therapies that can secure favorable reimbursement will have a significant advantage. This A&R content provides key insights for navigating the NSCLC market access landscape in the United States. The performance of branded NSCLC agents are evaluated against the economic and clinical expectations of payers and physicians.

  • Pub Date: December 2017
  • Author(s): Evrim Gurpinar

Request report

Related reports:
You may also be interested in: